Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2014

View Archived Issues

Amniox Medical initiates clinical trial of placenta-derived diabetic foot ulcer therapy

Lion Biotechnologies enters into trial agreement with Moffitt Cancer Center

Dong Wha completes phase III study of zabofloxacin in patients with COPD

Kalydeco approved in Europe in CF for eight non-G551D gating mutations

FUJIFILM presents novel PI3K and ERK-2 inhibitors

Researchers at Xencor divulge new heterodimeric proteins

Cubist Pharmaceuticals discloses novel TRPA1 antagonists

Novel HCV NS5A inhibitors disclosed by Merck & Co.

Daiichi Sankyo recaps pipeline progress of first quarter of fiscal 2014

Janssen Pharmaceutica patents novel gamma-secretase modulators

Kyowa Hakko Kirin seeks approval in Japan for KW-3357

Esteve confirms initiation of natural history study for Sanfilippo A syndrome

OncoCyte expands clinical development of bladder cancer diagnostic

First-in-human and in vitro results presented on novel drug for pre-transplantation desensitization

AFFiRiS reports results from phase I trial of Affitope PD-01A

Chugai Pharmaceuticals reports progress during second quarter 2014

Regeneron and Sanofi to use priority review voucher for alirocumab BLA

Shionogi to sell Ezose Sciences to Sumitomo Bakelite

Cara Therapeutics initiates abuse potential trial for CR-845

FDA approves olodaterol for COPD

Cortice Biosciences to develop heart failure drug for cognitive impairment

CHBP and caspase-3 siRNAs for renoprotection against ischemia reperfusion and CsA nephrotoxicity

Solasia gains exclusive worldwide rights to darinaparsin from Ziopharm Oncology

Alexion's eculizumab obtains European orphan drug designation for myasthenia gravis

Phase III trial initiated by Isis Pharmaceuticals for ISIS-SMNRx in infants

FDA approves empagliflozin for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...